Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib combined with HAIC for second-line treatment and maintenance in gastroenteropancreatic neuroendocrine carcinoma with liver metastases
ChiCTR2200062534Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib, oxaliplatin, fluorouracil and folinic acid in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
surufatiniboxaliplatinfluorouracilfolinic acid
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on ChiCTR2200062534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062534.